Navigation Links
AtheroGenics Reports ARISE Trial Results for AGI-1067

Full Study Results to Be Presented at the American College of Cardiology's Scientific Session

WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) today announced that its ARISE Phase III clinical study of its lead drug candidate, AGI-1067, did not show a difference from placebo in its composite primary endpoint; however, it did achieve a number of other important predefined endpoints. These endpoints included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, myocardial infarction (heart attack) and stroke, as well as an improvement in several key diabetes parameters, including glycemic control.

A full description of the ARISE study results will be presented by the ARISE principal investigators, Jean-Claude Tardif, M.D., Director of Research; Professor of Medicine, Montreal Heart Institute; and Marc Pfeffer, M.D., Ph.D., Professor of Medicine, Harvard Medical School; Senior Physician in Cardiology at Brigham and Women's Hospital, at the Late Breaking Clinical Trials session (Room Hall A) at the American College of Cardiology (ACC) Scientific Session in New Orleans on Tuesday, March 27 at 9:35 a.m. CDT.

While the company is disappointed that the composite primary endpoint was not met, it is encouraged by the positive results demonstrated in a number of disease states. As a result of the review of this data, the company has determined that the further development of AGI-1067 is important and the company currently intends to continue to pursue opportunities for development. The company will continue to review the data of the clinical study to prepare for discussions with the FDA to evaluate development paths forward for the drug.

A preliminary analysis of the safety data indicated th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AtheroGenics Reports ARISE Trial Results for AGI
(Date:7/2/2015)... According to a new market research ... Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, ... published by MarketsandMarkets, the global Neuromodulation Market is estimated at ... Billion by 2020, at a CAGR of 11.2% during the ... 4 market data T ables and ...
(Date:7/2/2015)... , June 25, 2015 Research ... "Cancer Diagnostics Market by Technology, Imaging and by Application - Forecast ... cancer diagnostics market is expected to reach $13.1 Billion in 2020 ... of 12.9%. The market is dominated by ... Asia , and Rest of the World (RoW). ...
(Date:7/2/2015)... July 2, 2015  The Green Exchange, Inc., the ... first HIPAA compliant mobile app that connects cannabis growers ... medical marijuana, announced today that their service provides the ... Meadow and more than half a dozen other delivery ... Loud Cannabis is unique in that it connects ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
... Zyga Technology, Inc. announced today that the U.S. ... company 510(K) clearance to market the SImmetry™ Sacroiliac ... System is intended for treating conditions including degenerative ... Joint Fusion System consists of a range of ...
... N.Y., Jan. 18, 2011 Vasomedical, Inc. ("Vasomedical") (OTC ... of medical devices, today announced financial results of the ... world leader in the noninvasive treatment of cardiovascular diseases. ... Diagnostics d/b/a VasoHealthcare , commenced operations on July ...
Cached Medicine Technology:Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 2Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 3Vasomedical Reports Financial Results for the Quarter Ended November 30, 2010 4
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness ... where they provide members of the Red Deer community with free fitness training and ... fitness training, games, food, events and entertainment raised thousands of charity dollars and ended ...
(Date:7/2/2015)... ... ... is pleased to announce the opening of its newest location in Dallas, Texas. The opening ... yogurt chain was listed as #22 on the Inc. 500 list of fastest growing companies ... is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are ...
(Date:7/2/2015)... ... July 02, 2015 , ... The American Association of Poison ... Stop Overdose Stat (S.O.S.) Act of 2015 on June 23, 2015. Together with ... to decrease drug overdose – especially of heroin and opioid medication – by ...
(Date:7/2/2015)... ... July 02, 2015 , ... With summer in full swing, Americans are flocking to Canada’s many ... top spots for fishing in the world, and it’s easy to understand why. From the ... great fish. , Recreational fishing is a huge industry, and Americans make up the ...
(Date:7/2/2015)... ... ... Americans celebrate the Fourth of July outdoors this weekend, local physicians are warning that ... Safety Month, and physicians at American Family Care and AFC Doctors Express urgent care ... skin cancers can be found early with regular skin exams. Physicians can give these ...
Breaking Medicine News(10 mins):Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4
... Digestive Health and Nutrition has announced the 2008 ... grants have been awarded to seven outstanding young ... the field of gastrointestinal research. , The ... total award of $225,000 to help support his ...
... YORK, May 30 We know ... to,our skin -- but what about ... Listen to this report from Transitions ... journalists can access video, audio, text, ...
... Members of District,1199C of the National Union of ... ratified a four-year contract agreement with,Hahnemann University Hospital ... and benefits., District 1199C represents some 1,300 ... the hospital following some 16 and a half ...
... of toxic free radicals from hypertension, study finds , , ... that the drug BH4 may hold promise as a treatment ... study. , Currently, BH4 is used to treat a genetic ... toxic buildup of a molecule called phenylalanine can cause brain ...
... Mayo Clinic researchers have developed an animal model that can ... and p19, in the aging process. Scientists knew that both ... mice age, but their role in the aging process was ... provides gas to accelerate cellular aging, while p19 stops that ...
... Wins Appeals of Major Aspects of New Jersey Cases, ... today that it is gratified that a Texas appeals court,overturned ... Brazoria County,and rendered a judgment in favor of Merck in ... first VIOXX case to go to trial after the,Company voluntarily ...
Cached Medicine News:Health News:7 outstanding young gastroenterologists receive AGA Foundation 2008 Research Scholars Award 2Health News:7 outstanding young gastroenterologists receive AGA Foundation 2008 Research Scholars Award 3Health News:7 outstanding young gastroenterologists receive AGA Foundation 2008 Research Scholars Award 4Health News:Genetic Disorder Drug Helps Reverse Heart Muscle Enlargement 2Health News:Merck Wins Appeal of First VIOXX(R) Case to go to Trial 2Health News:Merck Wins Appeal of First VIOXX(R) Case to go to Trial 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: